Maiwald blog articles
The European Patent Office (EPO) has announced that its fees will increase from 1 April 2024
The European Patent Office will increase most of its fees by an average of around 5% as of April 1, 2024. The fee increase will be significantly higher for the 3rd and 4th ren...
Continue reading
European Parliament Supports Use of Some Plants Generated By New Genomic Techniques (NGT) But Opposes Patents for all NGT Plants
In a vote held on 7 February 2024, the European Parliament (EP) approved a proposal to
Continue reading
Determining the value in dispute in patent nullity proceedings if the pharmaceutical product in question does not make use of the teaching of the contested patent – Value in Dispute V
In nullity appeal proceedings, on the application of the appellant the Federal Court of Justice ruled on 23 January 2024 (case no. X ZR 161/23 - not published yet) to signific...
Continue reading
Decision on inventive step casts new light on EBA’s ‘plausibility’ guidance: T 0116/18 and a review after 10 months of G 2/21
In March last year, the much-awaited decision of the Enlarged Board of Appeal (EBA), G 2/21, issued on the topic of “plausibility”, a catchword much appli...
Continue reading
Paris, Munich, Milan – first revision of the UPCA adopted
It has been agreed upon for several weeks and was already confirmed at the meeting of the Administrative Committee of the Unified Patent Court (UPC)
Continue reading
Maiwald is pleased to be a member of the UPCLA network
What is the UPCLA network? The UPCLA network, created in 2014, is a non-exclusive network of European law...
Continue reading
